Tegaserod (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tegaserod" in English language version.

refsWebsite

Global rank English rank

3web.archive.org

1^st place

1^st place

4^th place

4^th place

447^th place

338^th place

2^nd place

2^nd place

low place

low place

low place

low place

2,726^th place

1,608^th place

1semanticscholar.org

11^th place

8^th place

1prnewswire.com

406^th place

258^th place

doi.org

Beattie DT, Smith JA, Marquess D, et al. (November 2004). "The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo". Br. J. Pharmacol. 143 (5): 549–60. doi:10.1038/sj.bjp.0705929. PMC 1575425. PMID 15466450.
Loughlin J, Quinn S, Rivero E, Wong J, Huang J, Kralstein J, Earnest DL, Seeger JD (2010). "Tegaserod and the Risk of Cardiovascular Ischemic Events: An Observational Cohort Study". J Cardiovasc Pharmacol Ther. 15 (2): 151–7. doi:10.1177/1074248409360357. PMID 20200325. S2CID 37964792.

fda.gov

"FDA approves first treatment for women with irritable-bowel syndrome". Food and Drug Administration. Archived from the original on February 5, 2007. Retrieved March 30, 2007.
"FDA Announces Discontinued Marketing of GI Drug, Zelnorm, for Safety Reasons". FDA Press Release. 30 March 2007.

newswire.ca

"Novartis suspends Canadian marketing and sales of Zelnorm in response to request from Health Canada". Retrieved 2007-03-30.

nih.gov

pubmed.ncbi.nlm.nih.gov

Beattie DT, Smith JA, Marquess D, et al. (November 2004). "The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo". Br. J. Pharmacol. 143 (5): 549–60. doi:10.1038/sj.bjp.0705929. PMC 1575425. PMID 15466450.
Loughlin J, Quinn S, Rivero E, Wong J, Huang J, Kralstein J, Earnest DL, Seeger JD (2010). "Tegaserod and the Risk of Cardiovascular Ischemic Events: An Observational Cohort Study". J Cardiovasc Pharmacol Ther. 15 (2): 151–7. doi:10.1177/1074248409360357. PMID 20200325. S2CID 37964792.

ncbi.nlm.nih.gov

Beattie DT, Smith JA, Marquess D, et al. (November 2004). "The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo". Br. J. Pharmacol. 143 (5): 549–60. doi:10.1038/sj.bjp.0705929. PMC 1575425. PMID 15466450.

novartis.com

pharma.us.novartis.com

"New Data for Zelnorm". Archived from the original on December 9, 2007. Retrieved March 30, 2007.

prnewswire.com

WorldMeds, U. S. "FDA approves the reintroduction of Zelnorm™ (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65". www.prnewswire.com (Press release). Retrieved 2019-09-17.

semanticscholar.org

api.semanticscholar.org

Loughlin J, Quinn S, Rivero E, Wong J, Huang J, Kralstein J, Earnest DL, Seeger JD (2010). "Tegaserod and the Risk of Cardiovascular Ischemic Events: An Observational Cohort Study". J Cardiovasc Pharmacol Ther. 15 (2): 151–7. doi:10.1177/1074248409360357. PMID 20200325. S2CID 37964792.

web.archive.org

"New Data for Zelnorm". Archived from the original on December 9, 2007. Retrieved March 30, 2007.
"FDA approves first treatment for women with irritable-bowel syndrome". Food and Drug Administration. Archived from the original on February 5, 2007. Retrieved March 30, 2007.
"Zelnorm" (PDF). Novartis. Archived from the original (PDF) on 2007-04-10. Retrieved 2007-03-30.

zelnorm.com

"Zelnorm" (PDF). Novartis. Archived from the original (PDF) on 2007-04-10. Retrieved 2007-03-30.